today's Pick
Drugs aim to help elderly rebuild muscle
Publish Date: Apr 28, 2014
Drugs aim to help elderly rebuild muscle
  • mail
  • img
newvision

In 1997, scientist Se-Jin Lee genetically engineered "Mighty Mice" with twice as much muscle as regular rodents. Now, pharmaceutical companies are using his discovery to make drugs that could help elderly patients walk again and rebuild muscle in a range of diseases.

Novartis AG, working with biotech company MorphoSys AG, has the most advanced of these. Sanofi, Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer Inc. and closely held Atara Biotherapeutics are working on earlier-stage drugs. They are all in clinical or earlier-stage testing; the first could be approved in 2016.

"I am very optimistic about these new drugs," says Dr. Lee, a professor of molecular biology at Johns Hopkins University in Baltimore, who isn't involved in any of the drug trials.

"The fact that they're so far along means to me they must have seen effects."

Myostatin is a naturally occurring protein that curbs muscle growth. The drugs act by blocking it, or blocking the sites where it is detected in the body, potentially rebuilding muscle.

"I think the enthusiasm around myostatin is quite clear," says Nathan LeBrasseur, an associate professor and muscle specialist at the Mayo Clinic in Rochester, Minn. "If you were to ask for the perfect drug target, it's hard to argue against myostatin because it's so unique to skeletal muscle."

The ultimate prize for these drugs would be in treating the elderly.

Experts say muscle wasting and Alzheimer's—the decline in physical and cognitive functions, respectively—are the two major causes of institutionalization among the elderly.

One of the most important aspects of aging is frailty, which means you slow down and become weaker. "A lot of that is due to muscle strength, which we are looking to improve," says Mark Fishman, head of the Novartis Institutes for Biomedical Research.

Novartis and Sanofi are both testing their drugs in age-related muscle wasting, called sarcopenia. Lilly is testing its drug in elderly patients undergoing hip replacements or those recovering from falls.

"However you cut it, muscle wasting that has an impact on function is a very, very large patient population," says Bill Evans, a specialist in aging and muscle-metabolism at GlaxoSmithKline.

"It really depends where the regulators put the cutoff point, but my guess is it could affect 15% to 20% of the population over the age of 65 or 70."

Still, there are major hurdles to getting a sarcopenia drug approved. Regulators haven't yet defined sarcopenia as a disease, meaning there is no easy way to approve a drug to treat it.

"People tend to look at muscle loss as something that's just an inevitable process of aging," says Dr. Lee.

Drug companies also fear the herculean task of recruiting thousands of elderly patients—preferably not on other medications—for expensive, multiyear clinical trials.

"I think a number of companies have pulled out because there's not the grand-slam home run," says Dr. Evans.

Another concern is misuse, by athletes, bodybuilders or by those looking for an antiaging elixir, even when muscle wasting isn't the problem.

"If you think your mother can be kept out of a nursing home by using a compound—I think there's going to be a pretty large demand for something like that," he adds.

The drugs are still some way off being approved to treat elderly patients. But Dr. Lee is eager to see any medical application for his discovery, after a series of myostatin drug failures in the late 2000s.

Wyeth, now part of Pfizer, and U.K. drug group Shire PLC, in partnership with Acceleron Pharma Inc., both stopped myostatin drugs in development for muscular dystrophy.

Patients in Shire trials showed some unexplained nose and gum bleeding. Planned trials by Amgen Inc. and others were halted.

Myostatin drugs got an "early blemish," says Dr. LeBrasseur. The new treatments work in a slightly different way.

Hopes for Novartis's drug BYM338 are now high. Analysts estimate peak annual sales of $4.9 billion, according to a study compiled by consultancy Defined Health, cited by MorphoSys. J.P. Morgan analysts give an estimate off $3.4 billion.

The most advanced testing of BYM338 is in patients with a rare muscle-wasting disease called sporadic inclusion-body myositis. In trials, patients showed a small increase in their thigh muscle volume, and were able to walk farther than those taking a placebo, although the effects waned after treatment.

BYM338 is now in the late stages of clinical testing in the disease, with data from another trial expected in late 2015. Drugs for rare diseases can gain swift approval after relatively small trials.

Myostatin drugs are also being tested for muscle wasting caused by a chronic illness—a condition called "cachexia." That would be a far larger market.

By some estimates, cachexia is responsible for nearly a third of cancer deaths, as well as leading to the deaths of tuberculosis, heart-disease and lung-disease patients. Current appetite-stimulant treatments aren't always effective, and steroids can have bad side effects.

Others think the drugs could even be used to treat obesity and Type 2 diabetes one day, since building more muscle means a bigger storage area for sugars that might otherwise accumulate in the liver or pancreas.

Building muscle also increases the body's need for calories, which means patients burn off more of the food they eat.

"There's not a single drug on the market today that targets muscle growth in diabetics," says Dr. LeBrasseur. "That's pretty profound when you think of muscle playing such a key role in metabolism."

Still, he cautions there is a lot of work ahead.

"One thing we don't understand yet is why myostatin is released from muscle—is it playing an important role in other organ health? I think it's great we're going after this as a drug target, I just feel like we need to understand the biology a little bit better."

Source: WSJ

The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact digital@newvision.co.ug

  • mail
  • img
blog comments powered by Disqus
Also In This Section
Ebola death toll rises to 1,427
THE death toll from the Ebola outbreak sweeping through west African countries has risen to 1,427 out of more than 2,600 cases...
SpaceX rocket explodes during test flight
A SpaceX rocket exploded in midair during a test flight Friday, though no one was injured, as the company seeks to develop a spacecraft that can return to Earth and be used again....
Pakasa Forum: Ask President Kenyatta
The much-anticipated fourth edition of Vision Group''s Pakasa Forum is on in Kampala, with Kenyan President Uhuru Kenyatta a part of the business conference....
Pick your Pakasa access pass at New Vision offices
Access passes to the fourth edition of Vision Group’s Pakasa Forum on Saturday are now available at the New Vision reception on Plot 19/21, First Street, Industrial Area....
Museveni to pay  10% tuition hike for Makerere students
President Yoweri Museveni will shoulder the burden of paying the additional 10% fees slapped on the first year privately sponsored Makerere University students....
Senegal closes border as UN warns on Ebola flare-up
Senegal has become the latest country to seal its border with a west African neighbour to ward off the deadly Ebola virus, as the new UN pointman on the epidemic said preparations must be made for a possible flare-up of the disease....
Will strict traffic laws reduce road accidents?
Yes
No
Can't Say
follow us
subscribe to our news letter